跳至主要内容
临床试验/TCTR20230530004
TCTR20230530004已完成4 期

Protein-bound uremic toxin lowering effects of sevelamer in end-stage kidney disease receiving hemodialysis with hyperphosphatemia: a randomized controlled trial

Faculty of medicine, CHulalongkorn university0 个研究点目标入组 140 人开始时间: 2023年5月30日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. Age more than 18 years old
  • 2. Chronic kidney disease receiving hemodialysis for more than 3 months
  • 3. Hyperphosphatemia at least 5.5 mg/dL or currently receiving phosphate binders
  • 4. Consent to the study

排除标准

  • 1. Severe vascular calcification defined as symptomatic peripheral vascular disease, history of amputation due to peripheral vascular occlusion, recent cerebrovascular disease within 6 months and calciphylaxis
  • 2. Baseline serum calcium more than 10.0 mg/dL before randomisation
  • 3. Untreated secondary or tertiary hyperparathyroidism with PTH more than 1000 pg/mL
  • 4. Pregnancy
  • 5. Recent any routes on antibiotics within 2 weeks
  • 6. Planned kidney transplantation within 6 months
  • 7. Patients with terminal illness, life expectancy less than 6 months
  • 8. Active infection or active malignancies
  • 9. Likely to non-compliance
  • 10. Patients receiving hemodiafiltration

研究者

相似试验